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Abstract
Reversible phosphorylation of proteins, executed by kinases and phosphatases,
is the major posttranslational protein modification in eukaryotic cells, causing them
to become activated or deactivated. This intracellular event represents a critical
regulatory mechanism of several signaling pathways and can be related to a broad
number of diseases, including cancer. Few decades ago, protein tyrosine phospha-
tases (PTPs) were considered as tumor suppressors. However, nowadays, accumu-
lating evidence demonstrates that a misregulation of PTP activities plays a crucial
and decisive role in cancer progression and metastasis. In this chapter, we will focus
on the molecular aspects that support the crucial role of PTPs in cancer and in turn
make them promising for prediction, monitoring, and rational appropriate therapy
selection of individual patients.
Keywords: protein tyrosine phosphatases, cancer hallmarks, tumor suppressor,
metabolism, epithelial-mesenchymal transition
1. Introduction
Protein tyrosine phosphorylation plays a key role in cellular biology, once it can
create a new recognition site for protein-protein interactions, control protein sta-
bility, and specify the protein location, and, more importantly, regulates enzymatic
activity. Therefore, this intracellular event represents a critical regulatory mecha-
nism of several signaling pathways and, once it is dysregulated, can be related to a
broad number of diseases, including tumor development. Reversible phosphoryla-
tion of proteins is controlled reciprocally by both protein tyrosine kinases (PTKs)
and protein tyrosine phosphatases (PTPs). These phosphatases are hydrolases that
preferentially act on phosphotyrosine residue of a wide range of proteins, having as
products dephosphorylated protein at tyrosine residue and inorganic phosphate.
PTPs consist of a large protein superfamily with 107 members that can be divided
into four families (class I, II, III, and IV) according to differences in the amino acid
sequence at their catalytic domains and the amino acid used in the catalytic reac-
tion, cysteine-based PTPs (class 1, 2, and 3) and aspartate-based PTPs (class 4)
[1, 2]. So far, most of PTPs have been reported to act as tumor suppressors;
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however, some PTPs can also act as oncogenes depending on the tumor stages or the
expression of their interacting partners.
Along human tumor development, cells acquired biological plasticities that were
firstly defined by Hanahan and Weinberg, as hallmarks of cancer. These authors
proposed some capabilities of cancer cells that contribute for the disease complex-
ity, aggressiveness, and invasiveness: sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing
angiogenesis, deregulating cellular energetics, avoiding immune destruction, and
activating invasion and metastasis [3]. Surprisingly, in the last decade, some reports
have shown the relevance of PTPs for tumor cell plasticities. In this chapter we aim
to draw an organized picture of the molecular mechanisms by which PTPs take part
on tumor biological plasticity acquisition (Figure 1).
2. PTPs modulate energetic metabolism in tumors
Under normal conditions, cell metabolism depends on a tightly coordinated
regulation of key regulatory enzymes and, consequently, metabolic pathways
responsible for converting nutrients into building blocks for synthetic macromole-
cules, energy production, and biomass. However, cancer cells display efficiency
Figure 1.
Schematic overview of the role of PTPs in tumor plasticity. During tumor progression, cells acquire extra
mutations and reprogram their metabolism in order to sustain proliferation, migration, and survival. These
capacities are in part sustained by key signaling pathways in which PI3K, AKT, MAPK, and mTOR have
central roles. In this context, hyperactivation and loss of specific PTPs are crucial for keeping these kinases
active.
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capacity in reprogramming their metabolism through genetic or epigenetic changes
in order to get survival, proliferation, migration, invasiveness, and resistance to
death stimuli [5]. In recent years, it has been demonstrated that PTPs display a key
role in favoring cancer cell metabolic plasticity.
2.1 PTPs and Warburg effect
Otto Warburg showed that tumor cells substantially metabolize glucose to lac-
tate, even with the availability of oxygen. Under normal conditions, glucose is
metabolized to pyruvate by a series of enzymatic steps in the glycolytic pathway,
which is subsequently oxidized by the TCA and respiratory chain, generating CO2,
H2O, and 32 or 34 molecules of ATP per glucose molecule, while in glycolysis, 2
ATPs/glucose are produced. This alteration in glucose metabolism depends on
increased transcription of GLUTs, glycolytic enzymes, and oncogenes and increased
demand of mitochondrial metabolism for biosynthetic processes [4–6].
Until a few years ago, the importance of protein kinases for the Warburg effect
had been focused on several studies. However, recently, in the discovery that PTPs
also have relevance in tumor onset and progression, attention has been given to the
role of these phosphatases in tumor metabolism, as it is the case of Cdc25A,
LMWPTP, PRL-3, and PTEN.
Cdc25A—Until 2016 it was believed that the relevance of Cdc25A in cancer was
due to its positive effect on CDK. However, Liang and collaborators [7] performed
an elegant study showing the Cdc25A as a positive regulator of PKM2 in human
glioblastoma specimens. PKM2 catalyzes the conversion of phosphoenolpyruvate to
pyruvate, the last step of glycolysis pathway. These authors described that the
EGFR activation triggers the phosphorylation of Cdc25A at Y59 residue, mediated
by Src. Consequently, the interaction between Cdc25A and PKM2 is favored at a
nuclear compartment, leading to PKM2 dephosphorylation at S37, and in turn
induces PKM2-dependent β-catenin transactivation and c-Myc-upregulated expres-
sion of the glycolytic genes GLUT1, PKM2, and LDHA [7].
LMWPTP—Our group demonstrated that, in chemoresistant chronic myeloid
leukemia cells, the LMWPTP was overactivated and cooperated to Warburg effect.
A downregulation of mitochondrial proteins—PDH1, SDHA, and VDAC— was also
observed, while GLUT 1 expression and production of lactate were increased [8].
Later on, Lori and colleagues performed a phosphoproteomic analysis of A375
melanoma cells with silenced LMWPTP. These authors identified six possible sub-
strates, of which four, PKM2, GAPDH, α-enolase, and triose phosphate isomerase,
take part in the glycolytic pathway. In contrast to the findings reported by Faria and
coworkers, it was observed that the inhibition of LMWPTP leads to an inactivation
of PKM2, which causes a decrease in glycolytic flux and increase of GLUT1 and
hexokinase 2 [8, 9].
PRL-3—It was reported that when colorectal cancer cells (LoVo cell line)
overexpress, this phosphatase had an increase of glucose consumption and lactate
production in comparison to LoVo cell line wild type. Accordingly, high amount of
HK2, PKM2, and LDH were detected when PRL-3 is overexpressed [10]. Impor-
tantly, these authors also reported similar results when patient colorectal carcinoma
samples were screened. PRL-3 displays a lower expression level in adjacent normal
tissue but was overexpressed in colorectal carcinoma lesions. Furthermore, there
was a positive correlation between the expression of glycolytic enzymes (GLUT1,
HK2, PKM2, LDHA) and PRL-3.
PTEN—In different models (MEFs, prostate cancer cell lines, xenografts,
genetically modified mouse and patient prostate cancer samples), the loss of PTEN
specifically increases the expression of HK2 [11]. More recently, it was reported that
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the knockdown of PTEN in prostate cancer cells (DU145 cell line) leads to an
increase of lactate, pyruvic acid, succinic acid, citric acid, fumaric acid, malic acid,
and 2-ketoglutarate, in comparison to DU145 wild type [12]. These findings indicate
that glycolysis and glutaminolysis pathways are active in prostate cancer DU-145
cells when PTEN is not functional. Accordingly, it was demonstrated that the PTEN
higher expression compromises the proliferation and Warburg effect, in melanoma
and breast tumor, by dropping the expression of HIF1 and increasing the mito-
chondrial function, which are, at least in part, caused by decreasing glucose uptake
and inhibiting PI3K/mTOR pathway [13–16].
2.2 PTPs and glutamine/lipid metabolism
Some tumor cells become “addicted” to glutamine, once this amino acid can
provide energy and substrates necessary for cell division. As a consequence, the
tumor increases the mass of tumor cells and controls the potential redox through the
synthesis of NADPH [17]. PTEN knockdown, in prostate cancer, reduces the protein
level of GLS, enzyme involved in the glutaminolysis pathway, and increases the
FASN expression [12]. Tumor cells also exhibit substantial alterations in lipid metab-
olism. During fast growth and aggressive progression, tumor cells required many
metabolic intermediates and coordinate the activation of lipid synthesis leading to
membrane formation, energy storage, and second messenger production [17, 18].
3. PTPs favor tumor growth through survival positive regulation, and
cell death resistance
While normal cells tightly control the synthesis, secretion of growth factors, and
proliferative signaling pathways, in order to ensure cellular homeostasis, cancer
cells carry one or more defects along the signaling pathways from extracellular
compartment, for example, growth ligands and their receptors, to intracellular
mediators, such as PI3K, MAPK, and Akt, which give them survival advantages
[19, 20]. In this context, PTPs’ overexpression through gene amplification, loss, or
inhibition contributes for aberrant signaling and, in turn, promoting tumor cell
survival as exemplified below:
CDC25A, CDC25B, and CDC25C—CDC25A regulates cell cycle transition,
from G1 to S phase, where it activates the cyclin E/CDK2 complex, whereas the
phosphatases CDC25B and CDC25C act in the G2/M phase progression [21, 22].
Deregulations of these enzymes are correlated with imbalance in the cell cycle,
genetic instability, and uncontrolled proliferation. In addition, the high expression
level of these proteins is related to tumorigenesis [23, 24]. For instance, the
overexpression of CDC25A was related to proliferation of breast, colon, hepatocel-
lular, ovarian, lung, and nonmelanoma cancers [25]. Besides propitiating cancer cell
proliferation, it was reported that CDC25A modulates Foxo1, consequently activat-
ing the expression of matrix metalloproteinase (MMP)-1, key mediator of cell
dissemination. Moreover, the CDC25B overexpression was associated with gastric
cancer, and its knockdown reduces the proliferation rate of gastric cells [26].
EYA—EYA dephosphorylates tyrosine residues of H2AX, a protein involved
with DNA repair that prevents cell death caused by damage to the DNA molecule.
Chemical inhibition of EYA phosphatase diminished angiogenesis and tumor
growth [27]. WD-repeat-containing protein 1 (WDR1) is a specific substrate of
EYA3; thus, this PTP can modulate cytoskeletal reorganization [28]. Another iden-
tified substrate of EYA is ERβ, which its dephosphorylation decreases the antitumor
potential [29].
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LMWPTP—In normal cells, the increase of LMWPTP expression was associated
with a reduction of PDGFR phosphorylation, consequently dropping in the mito-
genic capacity [30]. However, later on, LMWPTP was described as a positive
modulator of Ras-MAPK, FGF, and Eph receptors [31, 32]. It was also reported that
the overexpression of LMWPTP contributes for invasive profile and primary sar-
coma formation in nude mice [33]. In this context, higher LMWPTP amount
(mRNA and protein) in primary human prostate cancer in relation to normal
adjacent tissue was found. Interestingly, the high level of mRNA of LMWPTP was
detected in lymph nodes, an indication that this phosphatase takes part in the
metastasis process [34]. In the same study, 147 patients out of 481 with prostate
cancer presented higher expression of LMWPTP and worse clinical outcome [34].
Accordingly, the LMWPTP has been categorized as a potential biomarker for
recurrence prediction for prostate cancer [35]. The importance of the LMWPTP in
cancer progression was also reported in colorectal cancer. It was demonstrated that
the LMWPTP overexpression in colorectal cancer correlated to a higher potential to
liver metastasis [36]. Importantly, it was also demonstrated that the LMWPTP
knockdown decreases CRC cell survival and sensitizes them to chemotherapy [36].
PTP1B—PTP1B is overexpressed in several cancers, such prostate, ovarian,
stomach, and colorectal [37–40]. For instance, in esophagus squamous cell carci-
noma, this phosphatase overexpression is directly related to invasion and metastasis
[38]. Similar effect was described in lung cancer, which was due to Src and Erk
activation. Interestingly, the PTP1B knockdown in colorectal cancer cells decreases
proliferation rate by blocking β-catenin signaling, a pathway responsible for
supporting the cancer secondary site colonization [39, 41].
SHIP2—SHIP2 positively affects tumor cell proliferation and migration. For
instance, it was observed that the overexpression of SHIP2 in colorectal cancer was
associated with migration and invasive profile through AKT activation [42].
SHP2 (PTPN11)—SHP2 (PTPN11) propiciates activation of Ras and MAPK
triggered by mitogens (insulin, EGF, and lysophosphatidic acid) and cell adhesion.
Notably, it has been shown that this phosphatase controls cell shape by contributing
to cytoskeletal organization. In addition, SHP2 also regulates integrin-mediated cell
adhesion, spreading, and migration. Also, inhibition of SHP2 is accompanied by
expressive increase in the numbers of actin stress fibers and focal adhesion contacts.
In contrast, overexpression of the SHP2 mutant also increased the strength of cell-
substratum adhesion [43]. SHP2 has been considered as a proto-oncogene in several
human cancers such as leukemia, glioblastoma, gastric carcinoma, lung cancer, and
breast cancer. This phosphatase improves cancer progression and poor prognostic
by activation of Ras/Raf/ERK and PI3K/Akt/mTOR pathways [44]. In hepatocellu-
lar carcinoma, the overexpression of SHP2 correlates with malignant cancer profile.
Accordingly, it was reported that the inhibition of SHP2 diminishes metastasis by
inhibition of cell adhesion and migration [45].
During cell transformation to malignancy, tumor cells became expert in over-
coming a broad diversity of stresses, such as uncontrolled signaling regulation,
starvation, DNA damage, hypoxia, and also anticancer therapy. In this aspect,
different researchers have shown that PTPs are involved in tumor cells resistant to
chemotherapeutic agents.
DUSP1 or PTPN10—It was shown that DUSP1 inhibits the MAPK (JNK) by
dephosphorylation and in turn blocks apoptosis process. This effect might be one of
the explanations in which DUSP1 promotes cancer cells escaping from apoptosis.
Indeed, it has been reported that DUSP1 is involved in many cancers: gastric intes-
tinal, lung, breast, squamous cell carcinoma, and head and neck [46].
LMWPTP—Our group has reported that in chemoresistant human chronic
myeloid leukemia cells (Lucena-1), LMWPTP is around 20-fold more active than in
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their sensitive counterpart (K562). Importantly, the knockdown of LMWPTP in
Lucena-1 cells reverted chemoresistance to vincristine and imatinib mesylate and
culminated in inactivation of Src kinase and Bcr-Abl. Both kinases are well known
to have a relevant contribution in leukemogenesis [47].
PTPN3—Wang and collaborators [40] performed a very elegant study, in which
they found somatic mutations in six PTPs, including PTPN3, in colorectal, lung,
breast, and gastric cancers. Later on, it was reported that PTPN3 induces drug
resistance (cisplatin and doxorubicin) in ovarian cancer [48].
SHP2—A study using a RNA interference-based genetic screen in BRAF-mutant
colon cancer cells identified the SHP2 as one of the key mediators of intrinsic and
acquired resistance. Once this phosphatase maintains the receptor tyrosine kinases
activated, even in the presence of BRAF inhibitor, it is still possible to have activa-
tion of cell proliferation and survival through involvement of ERK [49].
4. PTPs contribute for metastasis through extracellular matrix
remodeling and epithelial-mesenchymal transition
In this chapter subtitle, we will focus on strategies for migration and invasion as
part of the metastasis process.
PTPs activate the extracellular matrix remodeling and epithelial-mesenchymal
transition. ECM is a three-dimensional noncellular scaffold crucial for life in
multicellular organisms which is dynamically and continuously remodeled. ECM is
mainly composed of water and almost 300 proteins, for example, collagens
(fibrillar forms such as I–III, V, XI and non-fibrillar forms), proteoglycan
(aggrecan and glycosaminoglycan such as heparin sulfate and hyaluronic acid),
and glycoproteins (especially elastin, laminins, and fibronectin) [50, 51]. This
essential component is considered an extremely organized meshwork in a strict
contact with cells providing both biochemical and biomechanical support. It is well
known that despite the physical support to cells, ECM also modulates cell differ-
entiation, migration, and proliferation [50, 52]. Therefore, abnormal ECM
remodeling (exacerbate deposition or degradation) can be observed during patho-
logical conditions such as fibrosis and cancer [50, 52]. In tumor microenviron-
ment, much of the ECM proteins are produced not only by stroma cells, e.g.,
cancer-associated fibroblasts [52], but also tumor cells can produce ECM proteins
[53]. Malignant transformation is characterized by changes in the organization of
cytoskeleton resulting in abnormal cell signaling related to cell-cell and to cell-
ECM adhesion, a phenomenon termed epithelial-mesenchymal transition (EMT).
EMT consists of the loss of epithelial cell characteristics to possess properties of
mesenchymal cells. Several studies have shown that the EMT contributes to tumor
progression, invasion, metastasis, and acquisition of therapeutic resistance. During
the EMT process, the cancer cells acquire a fibroblastic morphology with a positive
regulation of mesenchymal markers (N-cadherin, vimentin, and α-actin) and a
negative regulation of epithelial cell markers (E-cadherin, ZO-1, claudins,
occludins, and cytokeratin) as well as a regulation of transcription factors that are
associated with increased migratory capacity (Slug, ZEB1/ZEB2, Twist1/Twist2).
These factors bind to the E-cadherin gene promoter and repress it [54–56]. EMT
requires a rupture of basement membrane permitting invasion and migration of
cancer cells through the ECM, then causing remodeling, and creating a tumor-
permissive environment [57].
Characteristic loss of E-cadherin-mediated cell-cell adhesion is commonly found
during malignant transformation [58] in which process kinases and phosphatases
have key roles [59, 60]. Several PTKs, including SRC and EGFR, phosphorylate the
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cadherin-catenin complex on different residues, resulting in a loss of cell adhesion
[60]. For instance, PTP1B regulates cadherin-based adhesion by dephosphorylating
β-catenin at Tyr654 [61]. In addition to β-catenin, p120-catenin phosphorylation
increases binding and affinity to E-cadherin, and PTPμ appears to be a regulator of
p120-catenin phosphorylation status, also acts as a scaffold, and recruits similar and
regulatory molecules to sites of cell adhesion [61, 62]. SHP2 is also able to bind to
cadherin-catenin complex and integrin molecules [62].
Cell migration through ECM requires integrin-mediated adhesion as well as
turnover of focal adhesions [63]. A decrease in tyrosine phosphorylation by PTPs is
involved in the formation and disassembly of focal adhesions. For instance, PTPα is
required for the activation of Src kinase following integrin interaction [64], and the
dephosphorylation of p130 CRK-associated substrate, by PTP-PEST, is necessary
for disassembly of focal adhesions, enabling cell migration [64]. The relation
between PTPs and upstream regulators of cell matrix adhesion and Rho family of
small GTPases has also been shown [65]. Most Rho proteins have intrinsic GTPase
activity which is stimulated by GTPase-activating proteins (GAPs), and these GAPs
are modulated by phosphorylation at tyrosine sites. Consequently, PTPs can influ-
ence Rho protein activation through regulating the phosphorylation state of GAPs.
Sastry and colleagues showed that PTP-PEST overexpression reduces Rac1 (a kind
of G protein) activity resulting in protrusion and retraction during cell migration
[66]. On the other hand, SHP2 seems to have some contradictory action, while some
literatures reported a RhoA activity inhibition by SHP2 [67] and others suggested a
stimulation [43]. In addition, p190RhoGAP, a GAP for RhoA, is a target for SHP-2
and LMWPTP and, in turn, regulating cytoskeletal rearrangement [68].
Metalloproteinases (MMPs) are one of the most important ECM-remodeling
enzymes produced by tumoral cells, which are linked to tumorigenesis and metas-
tasis [69]. More recently, it was reported that MMPs promote cell survival, angio-
genesis [69], and induction of EMT [70]. Hwang and coworkers [71] observed that
the treatment of MCF-7 breast cancer cells with BVT948 (a PTP inhibitor)
decreases invasion through suppression of NF-κB-mediated MMP-9 expression. On
the converse side, PTPμ knockdowns resulted in elevated adhesion, invasion, and
proliferation of breast cancer cells due to activation of ERK and JNK signaling
pathway and consequent elevated MMP-9 activity [72]. It was demonstrated that
the overexpression of PRL-3 increased the migration and invasion capacity of DLD-
1 colorectal cancer cells, which was dependent on the expression of MMP-7 [73].
Maacha and coworkers demonstrated that the contribution of the PTP4A3 for
malignancy of uveal melanoma is related to MMP-14 [74]. Yuan and colleagues
found that overexpression of PTPN9 reduces invasion and decreases MMP-2 gene
expression in MDA-MB-231 cells through inhibition of STAT3 downregulation [75].
Interestingly, still in the context of breast cancer, William Du and his team [76]
analyzed the levels of microRNA-24 in patients with breast carcinoma and found
higher content of this microRNA in breast carcinoma samples than in benign breast
tissue. They also generated constructs expressing miRNA-24 and studied their
functions in vivo and in vitro. In vivo experiments in mice indicated that the
expression of miRNA-24 enhanced tumor growth, invasion, and metastasis to the
lung and decreased survival. Molecularly, in vitro and in vivo experiments showed
high EGFR phosphorylation but repressed expression of PTPN9 and PTPRF due to
direct target of these phosphatases by miRNA-24. Consistently, they found in
patients with metastatic breast carcinoma a higher phosphorylation of EGFR but
lower levels of PTPN9 and PTPRF. Another confirmation was the upregulation of
MMP-2 and MMP-11 but downregulation of MMP inhibitor (TIMP-2) which sup-
ports the roles of miRNA-24 in tumor invasion and metastasis in breast cancer
suggesting miRNA-24 as a potential target for cancer intervention. In another
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study, Liu and collaborators [41] observed that PTP1B promotes the aggressiveness
of brain cancer through decreasing PTEN levels and, consequently, promoting AKT
activation and increasing of MMP-2 and MMP-7. Previously, it was reported that
PTP1B promotes gastric cancer cell invasiveness through modulating the expression
of MMP-2, MMP-9, and MMP-14 [77]. Another interesting study shows the rela-
tionship of PTP1B and interruption of cell adhesion and induction of the anoikis
effect in cancer cells. Inhibition of PTP1B in breast cancer cells leads to cell death
and loss of extracellular matrix fixation, leading to negative regulation of cell adhe-
sion proteins and interrupted actin polymerization. They saw that with the inhibi-
tion of PTP1B the activity of Src is consequently decreased by the adhesion pathway
and motility is impaired [78].
Besides being involved in ECM remodeling by modulating MMP activities, PTPs
(PTEN, SHP2, PTP1B, PRL3, PTP1B, PTRB, and PTPN9) have a key role in signal-
ing cascades that promote expression of EMT markers.
DUSP1—It has been reported that the knockdown of DUSP1 culminates in low
migratory and invasive efficiency of non-small cell lung cancer (NSCLC). Similar
effect was also observed in in vivo model [79].
PTEN—It has been reported that the loss of PTEN or its negative modulation by
phosphorylation or microRNA propiciates EMT. For instance, in lung cancer cells,
the inactivation of PTEN stimulated the nuclear translocation of β-catenin and
transcription factors snail and slug [80]. The authors also observed that the PI3K/
AKT/GSK-3β pathway is essential for inducing EMT in PTEN-knocked-down cells.
The relation between PTEN and negative regulation of AKT/β-catenin pathway was
also described by Li and colleagues in squamous cell carcinoma of the esophagus
[81]. It was observed that the glycan-1, a cell surface proteoglycan, promotes cell
proliferation by regulating the PTEN/AKT/β-catenin pathway, which culminates in
a positive regulation of N-cadherin and β-catenin and a negative regulation of E-
cadherin. In colorectal cancer cells, the loss of PTEN is associated with a change in
E-cadherin protein expression which was linked to EMT [82]. Wang and co-authors
[83] reported that tetraspanin 1 induced liver cancer cell EMT via the PI3K/AKT/
GSK-3β pathway. These authors also show that the PTEN repression was funda-
mental for this process. In addition to the effects reported above, one event that is
associated with PTEN induction of EMT is the dysregulation of microRNAs. Studies
have shown that PTEN is a target of some microRNAs. Wu and collaborators [84]
showed that MiR-616-3p is upregulated in metastatic gastric cancer cells during
angiogenesis process, and PTEN was one of the targets of this microRNA. Li [85]
also showed that MiR-181-a is associated with lung cancer cell EMT through inhibi-
tion of PTEN protein expression. Another strategy to inhibit PTEN is via TGF-β
cascade. The phosphorylation of the PTEN C-terminus leads to a conformational
change, consequently provoking the loss of membrane binding and downregulation
of PTEN phosphatase activity [86].TGF-β derived from the tumor microenviron-
ment induces malignant phenotypes such as EMT and aberrant cell motility in lung
cancers, by at least in part, due to inhibition of PTEN by phosphorylation [87].
SHP2—Sun and coworkers reported that IL-6 induces SHP2 activation by phos-
phorylation, which was required for breast cancer cell EMT stimulation in response
to IL-6 [88]. This phosphatase also has a positive connection in lung cancer cell
EMT triggered by TGF-β1 [89]. In addition, these authors identified the protein
Hook1 as an interactor of SHP2 and classified this protein as an endogenous nega-
tive regulator of SHP2. The expression of Snail and Twist1, key mediators of EMT
process, has been positively modulated by SHP2 in oral cancer, via its interaction
with ERK1/ERK2 [89].
PTP1B—Hiraga and colleagues reported that PTP1B is one of the mediators of
pancreatic cancer cell EMT induced by TGF-β [90].
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PRL-1—This phosphatase causes activation of AKT, and inhibition of GSK3β,
consequently, contributes for elevated levels of Snail expression and decreased E-
cadherin expression. In agreement, the high level of this enzyme was associated
with more aggressive phenotype and poorer prognosis in hepatocellular carcinoma
patients [46].
PRL-3—PRL-3 activates the PI3K/PKB pathway and promotes EMT by
decreasing PTEN protein expression [23]. In addition, it was demonstrated that
expression of PRL-3 in hepatocellular carcinoma patients was positively correlated
with the expression of MMPs 1, 9, 10, and 12 [46].
PTRB—Overexpression of PTRB has an opposite effect on EMT markers:
decreased the expression of E-cadherin and increased the amount of vimentin [91].
5. PTPs that act as tumor suppressors
Tumor suppressors operate in different ways and compartments to limit cell
growth and proliferation. Besides the important contribution of PTPs in cancer
progression, some PTPs that act as tumor suppressors are described below:
PTEN—Is a central tumor suppressor, mainly due to its negative effect on key
pathways related to cell proliferation, survival, and metastasis: PI3K-Akt–mTOR,
NF-κB, and HIF [92, 93]. Therefore, the loss of PTEN, which occurs in the major of
the tumors, is correlated with tumor aggressiveness and low response to therapy. In
prostate cancer studies, PTEN has been shown to ameliorate the malignant pheno-
type by dephosphorylating the activator residue of PTK6 (Tyr 342), a kinase related
to a cancer aggressive phenotype [94]. In addition, other oncogenic kinases, such as
PDGFR and FAK, have been reported as a substrate of PTEN [95, 96]. Although the
molecular mechanisms by which PTEN acts as a tumor suppressor are well known,
until few years ago, there were not a lot of information about the posttranslational
regulation of PTEN. Recently, Park and collaborators [97] have reported two
mechanisms of PTEN regulation that directly are connected to its tumor suppressor
property: (a) deubiquitination by ubiquitin-specific protease 11 (USP11), responsi-
ble for increasing the stability of nuclear and cytosolic PTEN; (b) the level and
activity of PTEN are also autoregulated by this phosphatase via PI3K-forkhead
transcription factor (FOXO)-USP11 cascade [97].
SHP1 (PTPN6)—Has been described as a major negative regulator of MAPK,
JAK/STAT, and NF-κB signaling pathways [98, 99]. Therefore, SHP1 activity is
inversely related to cancer development. Indeed, the SHP1 expression in stomach
cancer is very weak. Accordingly, the overexpression of SHP1 in stomach cancer
cell lines induces a decrease of proliferation, migration, and invasion [100]. In
addition, Chen and colleagues showed that SHP1 dephosphorylates and inhibits
PKM2, a kinase that stimulates proliferation in hepatocellular carcinoma [46].
SHIP1—Is expressed only in hematopoietic-derived cells and acts as a negative
modulator of PI3K pathway [101]. It was described that the PTEN and SHIP1 loss is
deeply related to lymphoma survival [102].
PTPN9 (PTP-MEG2)—Low expression of this phosphatase predicted poor sur-
vival in patients with hepatocellular carcinoma. It was observed that PTPN9 indi-
rectly inhibits activity of STAT3 and STAT5 through direct dephosphorylation of
EGFR and HER2, in breast cancer [46]. In addition, the overexpression of PTPN9
decreases the phosphorylation of AKT protein at its activatory residue, which cul-
minated in diminishing the EMT process efficiency [103].
PTPN12 (PTP-PEST)—Regulates oncogenic tyrosine kinases such as HER2 and
EGFR and has a role in modulating EMT. Not surprisingly, it has been decreased or
lost in human hepatocellular carcinoma tissues, and by using this carcinoma cell
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lines as models, it was demonstrated that PTPN12 downregulation stimulated cell
migration [46].
FAP-1 (PTPN13)—Downregulates Src-ERK pathway by inhibiting EphrinB1
[104]. FAP-1 can also interact and dephosphorylate Her2, thus reducing the
aggressive potential of tumors that have high expression of this receptor [105]. It
was also demonstrated that overexpression of this phosphatase caused an
upregulation of the epithelial marker, E-cadherin, and downregulated mesenchy-
mal markers such as Snail, Slug, and MMP-9, which are a strong indication that
FAP-1 inhibits EMT in hepatocellular carcinoma progression [46].
DUSP2—It has been shown that DUSP2 is involved in P53-induced cell apopto-
sis; however, this phosphatase is dramatically reduced in different solid tumors
compared to their normal counterparts. Accordingly, it was reported that the
diminished DUSP2 leads to prolonged ERK phosphorylation, increased drug resis-
tance, as well as an inflammatory response due to overproduction of prostaglandin
in colorectal cancer [106]. It was also reported that DUSP2 knockdown in xenograft
tumors promotes higher vessel density and metastasis events from colorectal cancer
to the liver [107].
PTPRT (PTPρ)—Is commonly mutated in several types of cancer, including
colorectal cancer [40]. Many studies have reported the tumor suppressor potential
of this PTP, and among the possible substrates of this phosphatase are paxilin and
STAT3 [108, 109].
PTPRH—This phosphatase interacts with Grb2 and then modulates Ras path-
way activity. Studies have reported that PTPRH blocks cell growth and migration
by dephosphorylating proteins associated with focal adhesion, such as p130 [110].
PTPRD—It has been shown that patients with the high level of PTPRD display
better long-term survival rate and low chance of liver cancer recurrence. However,
the mechanisms underlying this action are not elucidated.
PTP receptor type F (PTPRF)—Is involved in Src kinase inactivation; there-
fore, it is not surprising that this enzyme is frequently downmodulated in hepato-
cellular carcinoma patients and upregulation of PTPRF is associated with better
prognosis [46].
PTP receptor type O (PTPRO)—Plays as a chronic lymphocytic leukemia,
lung, and breast tumor suppressor by inhibiting proliferation and stimulating apo-
ptosis, at least in part, due to STAT3 dephosphorylation [46].
PTP receptor S (PTPσ)—Is an important negative modulator of EGFR. There-
fore, the downregulation of this phosphatase has been connected to decreased
overall survival and high risk of postoperative recurrence in HCC patients [46].
6. Conclusions
Over the past two decades of research on PTPs, the field has achieved a great
progress in understanding the immense role of these phosphatases in cancer pro-
gression. Here, we presented an organized picture that clearly shows the participa-
tion/contribution of PTPs as key mediators of cancer plasticity, due to their loss of
function or overexpression. In summary the above compendium highlights the
importance of PTPs not only in cancer progression but also as potential targets for
therapeutic interventions. Indeed, during the transition from good to poor outcome
of different cancer subtypes, PTPs are extremely plastic, with the capacity to
readjust themselves across a wide spectrum of stimuli. This plasticity of PTPs
together with the loss of function of PTP suppressors provides tumor cells with all
conditions for growth, proliferation, and survival. Illustrative examples are PTEN
(loss), LMWPTP, PRL-3, and PTP1B serving as “signaling hubs” that connect dif-
ferent hallmarks (such as sustaining proliferative signaling, evading growth
10
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suppressors, resisting cell death, deregulating cellular energetics, and activating
invasion and metastasis). This connection might explain, at least in part, the great
capacity of tumor cells’ plasticity.
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Appendices and nomenclature
130 CRK p130 Crk-associated substrate (member of an adapter
protein family that binds to several tyrosine-
phosphorylated proteins)





DUSP1 (PTPN10) dual-specificity protein phosphatase 1
DUSP dual-specificity protein phosphatase
ECM extracellular matrix
EGFR epidermal growth factor receptor
EMT epithelial-mesenchymal transition
Eph ephrin
ERbeta estrogen receptor beta
ERK extracellular signal-regulated kinase
Eya eyes absent
FAK focal adhesion kinase
FGF fibroblast growth factor
FOXO-1 forkhead box protein O1
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GAPs GTPase-activating proteins or GTPase-accelerating
proteins
GLS glutamine synthetase
GLUT glucose transporter 1
GSK-3beta glycogen synthase kinase 3 beta
H2AX H2A histone family member X
HIF hypoxia-inducible factor
HK hexokinase
JAK Janus kinase 2
LDHA lactate dehydrogenase A
LMWPTP low-molecular-weight protein tyrosine phosphatase, also
known as ACP1
MAPK mitogen-activated protein kinase
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MEF mouse embryonic fibroblast
MMP-1 matrix metalloproteinase-1
mTOR mammalian target of rapamycin
NFKB nuclear factor kappa-light-chain-enhancer of activated B
cells
PI3K phosphatidyl inositol-3-kinase
PKM2 pyruvate kinase isozymes M2
PRL-3 phosphatase of regenerating the liver-3, also recognized
as PTP4A3
PTEN phosphatase and tensin homologue
PTKs protein tyrosine kinases
PTP σ protein tyrosine phosphatase sigma
PTP μ protein tyrosine phosphatase
PTP-PEST (PTPN12) PTP-PEST (PTP—proline, glutamic acid, serine, and
threonine rich)
PTP1B tyrosine-protein phosphatase non-receptor type 1
PTPN3 protein tyrosine phosphatase non-receptor type 3
PTPN11 protein tyrosine phosphatase non-receptor type 11
PTPN13 PTP also referred to as FAP1
PTPN9 tyrosine-protein phosphatase non-receptor type 9
PTPRδ protein tyrosine phosphatase receptor delta
PTPRF protein tyrosine phosphatase receptor type F
PTPRH receptor-type protein tyrosine phosphatase H, also
referred to as stomach cancer-associated protein tyrosine
phosphatase-1 (SAP-1)
PTPRO protein tyrosine phosphatase receptor type O
PTPρ protein tyrosine phosphatase receptor T
PTPs protein tyrosine phosphatases
Raf serine/threonine-specific protein kinase
Ras class of protein called small GTPase
Rho Ras homologue of small GTPase
RhoA Ras homologue of small GTPase member A
SHIP1 Src homology 2 (SH2) domain-containing inositol
polyphosphate 5-phosphatase 1
SHIP2 Src homology 2 (SH2) domain-containing inositol
polyphosphate 5-phosphatase 2
SHP1 Src homology 2 (SH2) domain-containing
phosphotyrosine phosphatase, also known as PTPN6
SHP2 Src homology 2 (SH2) domain-containing
phosphotyrosine phosphatase 2, also known as PTPN11
Slug SNAI2, a zinc finger transcription factor
Src proto-oncogene tyrosine-protein kinase
STAT3 signal transducer and activator of transcription type 3
TCA tricarboxylic acid cycle
TGFbeta transforming growth factor beta
Twist Twist-related protein
WDR1 WD-repeat-containing protein 1
ZEB 1/2 zinc finger E-box-binding homeobox ½
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